Bruls Annette 4

4 · Edwards Lifesciences Corp · Filed May 8, 2026

AI-generated summary of this filing

Updated May 9, 2026

Edwards Lifesciences CVP Annette Bruls Receives Stock Awards

What Happened

Annette Bruls, CVP, EMEACLA at Edwards Lifesciences (EW), was granted equity awards on May 7, 2026: time‑based restricted stock units (6,650 RSUs), performance‑based RSUs (target 33,700 PSUs), and stock options covering 6,650 shares. These awards have a grant price of $0 (awards, not purchases). On May 8, 2026 she had 84 shares surrendered/withheld to cover tax obligations at $82.76 per share (proceeds/value = $6,952).

Key Details

Grant dates: May 7, 2026 (awards and options); tax withholding: May 8, 2026.
Award amounts: 6,650 time‑based RSUs; 33,700 target performance RSUs (PSUs); 6,650 stock options. All awards show $0 acquisition price (grants).
Tax withholding: 84 shares withheld/disposed at $82.76 each, total ≈ $6,952.
Vesting: Time‑based RSUs and options vest beginning one year after grant in four equal annual installments (per footnotes). PSUs vest May 7, 2029 contingent on 3‑year performance (0%–200% of target).
Shares owned after the transaction: Not specified in this Form 4 (filing states it only reflects changes in beneficial ownership).
Filing timeliness: Form 4 filed May 8, 2026 for transactions dated May 7–8, 2026 — appears timely (no late filing indicated).

Context

These were compensation awards (not open‑market purchases or sales). The small 84‑share disposition was a tax withholding/payment related to the awards and is routine. Performance RSUs will only convert to shares if specified performance goals are met over the three‑year performance period; options and time‑based RSUs vest over four years. This Form 4 reflects changes in beneficial ownership only and does not identify other holdings.

Form 4

Period: 2026-05-07

CVP, EMEACLA

Transactions

Award
Common Stock
[F1]
2026-05-07+6,650→ 20,821 total
Tax Payment
Common Stock
2026-05-08$82.76/sh−84$6,952→ 20,737 total
Award
Employee Stock Option (Right to Acquire)
[F2]
2026-05-07+33,700→ 33,700 total
Exercise: $82.76From: 2027-05-07Exp: 2033-05-06→ Common Stock (33,700 underlying)
Award
Performance Rights
[F3]
2026-05-07+6,650→ 6,650 total
From: 2029-05-07→ Common Stock (6,650 underlying)

Footnotes (3)

[F1]These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
[F2]These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
[F3]Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Signature

Linda J. Park, Attorney-in-Fact|2026-05-08

1 file